2023
Outcomes with panobinostat in heavily pretreated multiple myeloma patients
Pan D, Mouhieddine T, Upadhyay R, Casasanta N, Lee A, Zubizarreta N, Moshier E, Richter J. Outcomes with panobinostat in heavily pretreated multiple myeloma patients. Seminars In Oncology 2023, 50: 40-48. PMID: 37005144, DOI: 10.1053/j.seminoncol.2023.03.006.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsDexamethasoneHumansHydroxamic AcidsIndolesMultiple MyelomaPanobinostatRetrospective StudiesConceptsMultiple myelomaStandard-of-care therapyResponse rateTriple-class refractory diseaseHigh-risk cytogeneticsClinical benefit rateMedian overall survivalProgression-free survivalRefractory multiple myelomaMultiple myeloma patientsHistone-deacetylase inhibitorsDescending order of frequencyMount Sinai HospitalOral optionOverall survivalRefractory diseaseMyeloma patientsBenefit ratePanobinostatAcademic medical centerTriple classPatientsMyelomaAgent combinationsSinai Hospital
2019
Relationship Between Hereditary Cancer Syndromes and Oncotype DX Recurrence Score
Casasanta N, Kipnis S, Linville L, Lipinski S, Knoedler A, Marino A, McHenry A, Biagi T, Stark E, Amdur R, Denduluri N, Rodriguez P, Isaacs C, Kaltman R. Relationship Between Hereditary Cancer Syndromes and Oncotype DX Recurrence Score. Clinical Breast Cancer 2019, 20: 125-130. PMID: 31526714, DOI: 10.1016/j.clbc.2019.07.004.Peer-Reviewed Original ResearchConceptsGermline mutation statusOncotype DX recurrence scoreBreast cancer patientsRecurrence scoreMutation statusOncotype DXAssociation of RSGermline mutationsCancer patientsHormone receptor-positive breast cancer patientsHereditary cancer riskGermline genetic testingGenetic risk assessmentHereditary cancer syndromesAssociated with germline mutationsBenefit of chemotherapyRetrospective analysis of dataMultivariate logistic regression modelLikelihood of recurrenceFisher's exact testMultivariate logistic regressionCounseling of family membersLogistic regression modelsNon-BRCA1/2BRCA2 genes